Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 5Breast 5Gynecologic 3Thoracic 2Head & Neck 2Genitourinary 2Gastrointestinal 2CNS 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Endocrine 1Dermatologic 1

Conditions

Leukemia, Plasma Cell 1

Interventions

Dexamethasone 47Lenalidomide 31daratumumab 24Bortezomib 23pomalidomide 19carfilzomib 15Specimen Handling 15Cyclophosphamide 15Calcium Dobesilate 15Biopsy 15Magnetic Resonance Spectroscopy 11talquetamab 9isatuximab 9Melphalan 9iberdomide 8dexamethasone acetate 8dexamethasone 21-phosphate 8auricularum 8fludarabine 7belantamab mafodotin 7selinexor 5X-Rays 5tocilizumab 4fludarabine phosphate 4elotuzumab 4Nuclear Medicine Department, Hospital 4trametinib 3dabrafenib 3Whole-Body Irradiation 3Thalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fluorodeoxyglucose F18 × Plasma cell × 30 days × Clear all
NCT07605416 2026-05-26

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
74 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡